Ethinylestradiol/etonogestrel vaginal - Organon - AdisInsight (original) (raw)
Alternative Names: Etonogestrel/ethinylestradiol; NuvaRing; SCH-900702
Latest Information Update: 05 Nov 2023
Price :
$50*
Note:
- Adis is an information provider.We do not sell or distribute actual drugs.
- Final gross price and currency may vary according to local VAT and billing address.
- Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
- A link to download a PDF version of the drug profile will be included in your email receipt.
At a glance
- Originator Organon
- Developer Merck & Co
- Class Alkylated estrogenic steroids; Hormonal contraceptives; Norpregnanes; Norpregnatrienes; Progesterone congeners
- Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
- Orphan Drug Status No
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pregnancy
Most Recent Events
- 12 Dec 2019 First Generic equivalent EluRyng™ approved and available in USA
- 25 Jan 2018 Ethinylestradiol/etonogestrel vaginal ring licensed to Grunenthal for commercialisation and distribution in Brazil, Central America, Colombia, Mexico and Peru
- 21 Sep 2017 No recent reports on development identified - Phase-III for Pregnancy (Prevention) in China (Vaginal)
You need to be a logged in or subscribed to view this contentRequest demo
If your organization or you do not have a subscription, try one of the following:
- Contacting your organization’s admin about adding this content to your AdisInsight subscription
- Buying a PDF version of any individual profile
- Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
- Working within your organization’s network
- Login with username/password or try toaccess via your institution
- Persisted access using your organization’s identifier stored in your user browser for 90 days
For assistance, contact us atasktheexpert.adisinsight@springer.com